sofenacin is developed by Mansoura University.

What development phase is sofenacin in?

sofenacin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

sofenacin

Mansoura University · FDA-approved active Small molecule Quality 0/100

Sofenacin, developed by Mansoura University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the university's research and development capabilities. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	sofenacin
Also known as	Solfenacin 10 mg
Sponsor	Mansoura University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

sofenacin CI brief — competitive landscape report
sofenacin updates RSS · CI watch RSS
Mansoura University portfolio CI